A medical condition previously known as Polycystic Ovary Syndrome has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a global review involving medical experts and patient advocacy groups.
The condition, which affects about one in eight women worldwide, impacts hormones, metabolism, reproductive health, mental health, skin condition and weight regulation.
More than 50 patient and professional organisations, including the Endocrine Society, participated in the process that led to the new name.
According to a press release by The Endocrine society on Tuesday, experts explained that the former name, Polycystic Ovary Syndrome, had for years created misconceptions about the condition by focusing mainly on ovarian cysts, despite evidence showing that abnormal cysts are not necessarily present in affected patients.
The renaming process was led by an endocrinologist, Professor Helena Teede of Monash University and Monash Health.
According to Teede, the previous terminology contributed to delayed diagnoses, poor awareness and inadequate treatment for many women living with the condition.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated.
“It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition.
“While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition,” said Teede, who is an Endocrine Society member.
The findings and details of the renaming process were published
This post was originally published on this site.
